Impact of timing and cycles of systemic chemotherapy on survival outcome of colorectal liver metastases patients treated by percutaneous microwave ablation

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013;24:792–800.
   PubMed Web of Science ®Google Scholar
• House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010;210:744–52, 752–5.
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol 2009;27:1829–35.
   PubMed Web of Science ®Google Scholar
• Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575–80.
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783):2103–14.
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–17.
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563–72.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721–7.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–19.
   PubMed Web of Science ®Google Scholar
• Kennedy TJ, Cassera MA, Khajanchee YS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience. J Surg Oncol 2013;107:324–8.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG. Colorectal carcinoma metastases in liver: Laser-induced interstitial thermotherapy – local tumor control rate and survival data. Radiology 2004;230:450–8.
   PubMed Web of Science ®Google Scholar
• Knudsen AR, Kannerup AS, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiol 2009;50:716–21.
   PubMed Web of Science ®Google Scholar
• Puls R, Langner S, Rosenberg C, Hegenscheid K, Kuehn JP, Noeckler K, et al. Laser ablation of liver metastases from colorectal cancer with MR thermometry: 5-year survival. J Vasc Interv Radiol 2009;20:225–34.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 2008;42:945–9.
   PubMed Web of Science ®Google Scholar
• Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012;23:2619–26.
   PubMed Web of Science ®Google Scholar
• Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT, Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005;236:132–9.
   PubMed Web of Science ®Google Scholar
• Yu J, Liang P, Yu X, Liu F, Chen L, Wang Y. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: Results in ex vivo and in vivo porcine livers. Eur J Radiol 2011;79:124–30.
   PubMed Web of Science ®Google Scholar
• Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: What are the differences? Curr Probl Diagn Radiol 2009;38:135–43.
   PubMedGoogle Scholar
• Livraghi T, Meloni F, Solbiati L, Zanus G, Collaborative Italian Group using AMICA system. Complications of microwave ablation for liver tumors: Results of a multicenter study. Cardiovasc Intervent Radiol 2012;35:868–74.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: Treatment with percutaneous microwave ablation – complications among cohort of 1136 patients. Radiology 2009;251:933–40.
   PubMed Web of Science ®Google Scholar
• Huang H, Liang P, Yu XL, Cheng ZG, Han ZY, Yu J, et al. Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder. Int J Hyperthermia 2015;31:40–7.
   PubMed Web of Science ®Google Scholar
• Wang J, Liang P, Yu J, Yu MA, Liu F, Cheng Z, et al. Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases. Oncol Lett 2014;8:323–6.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria – a 10-year update. Radiology 2014;273:241–60.
   PubMed Web of Science ®Google Scholar
• Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993;71(Suppl.12):4252–66.
   PubMed Web of Science ®Google Scholar
• Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66.
   PubMed Web of Science ®Google Scholar
• Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 2012;6:CD006317.
   PubMed Web of Science ®Google Scholar
• Gillams AR, Lees WR. Radiofrequency ablation of colorectal liver metastases. Abdom Imaging 2005;30:419–26.
   PubMed Web of Science ®Google Scholar
• Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg 2006;141:460–6; discussion 466–7.
   PubMedGoogle Scholar
• Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: Recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008;143:1204–12.
   PubMedGoogle Scholar
• Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197:728–36.
   PubMed Web of Science ®Google Scholar
• Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000;89:276–84.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shimada H, Nagano Y, Endo I, Sekido H, Togo S. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery 2006;139:263–73.
   PubMed Web of Science ®Google Scholar
• Correa-Gallego C, Fong Y, Gonen M, D'Angelica MI, Allen PJ, DeMatteo RP, et al. A retrospective comparison of microwave ablation vs radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol 2014;21:4278–83.
   PubMed Web of Science ®Google Scholar
• Ierardi AM, Floridi C, Fontana F, Chini C, Giorlando F, Piacentino F, et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. Radiol Med 2013;118:949–61.
   PubMed Web of Science ®Google Scholar
• Veltri A, Guarnieri T, Gazzera C, Busso M, Solitro F, Fora G, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med 2012;117:1139–51.
   PubMed Web of Science ®Google Scholar
• Van Tilborg AAJM, Meijerink MR, Sietses C, Van Waesberghe JHTM, Mackintosh MO, Meijer S, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: A potentially curative intervention. Br J Radiol 2011;84(1002):556–65.
   PubMed Web of Science ®Google Scholar
• Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009;19:1206–13.
   PubMed Web of Science ®Google Scholar
• Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007;246:559–65; discussion 565–7.
   PubMed Web of Science ®Google Scholar
• Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: Evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006;12:318–26.
   PubMed Web of Science ®Google Scholar
• Liang P, Dong B, Yu X, Yang Y, Yu D, Su L, et al. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. Am J Roentgenol 2003;181:1319–25.
   PubMed Web of Science ®Google Scholar
• Hamada A, Yamakado K, Nakatsuka A, Uraki J, Kashima M, Takaki H, et al. Radiofrequency ablation for colorectal liver metastases: Prognostic factors in non-surgical candidates. Jpn J Radiol 2012;30:567–74.
   PubMed Web of Science ®Google Scholar
• Nikfarjam M, Shereef S, Kimchi ET, Gusani NJ, Jiang Y, Avella DM, et al. Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol 2009;16:1860–7.
   PubMed Web of Science ®Google Scholar
• Reddy SK, Zorzi D, Lum YW, Barbas AS, Pawlik TM, Ribero D, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann Surg Oncol 2009;16:1809–19.
   PubMed Web of Science ®Google Scholar
• Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010;252:774–87.
   PubMed Web of Science ®Google Scholar
• Lu QY, Zhao AL, Deng W, Li ZW, Shen L. Hepatic histopathology and postoperative outcome after preoperative chemotherapy for Chinese patients with colorectal liver metastases. World J Gastrointest Surg 2013;5:30–6.
   PubMedGoogle Scholar
• Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007;11:860–8.
   PubMed Web of Science ®Google Scholar
• Kingham TP, Tanoue M, Eaton A, Rocha FG, Do R, Allen P, et al. Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol 2012;19:834–41.
   PubMed Web of Science ®Google Scholar
• Stang A, Oldhafer KJ, Weilert H, Keles H, Donati M. Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: A clinical score based proposal. BMC Cancer 2014;14:500.
   PubMed Web of Science ®Google Scholar
• Faitot F, Faron M, Adam R, Elias D, Cimino M, Cherqui D, et al. Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: A case-matched analysis of surgical and oncological outcomes. Ann Surg 2014;260:822–7; discussion 827–8.
   PubMed Web of Science ®Google Scholar
• Choi JH, Ahn MJ, Rhim H, Lee HW, Oh HS, Lee YY, et al. Radiofrequency ablation for metastatic hepatic tumor in colorectal carcinoma. Cancer Res Treat 2004;36:128–31.
   PubMedGoogle Scholar
• Parks R, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents. J Am Coll Surg 2007;204:753–61; discussion 761–3.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li S, Wan X, Li Y, Li B, Zhang Y, et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol 2013;25:442–6.
   PubMed Web of Science ®Google Scholar
• Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol 2014;15:601–11.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225–33.
   PubMed Web of Science ®Google Scholar